Focusing on niche markets with high medical needs, SymBio continues to in-license new drug candidates with confirmed POC (Proof of Concept) in human subjects from bio-ventures and pharmaceutical companies worldwide, aiming to shorten the development timeline to commercialization. SymBio will continue to proactively expand indications of existing products and introduce promising new drug candidates to build a robust product pipeline.